The American College of Cardiology/American Heart Association/The Obesity Society guidelines emphasize individualized treatment plans incorporating lifestyle modification, behavioral therapy, pharmacotherapy when appropriate, and metabolic/bariatric surgery for eligible patients
Official Injection Sites for GLP-1 Medications According to their FDA-approved prescribing information, GLP-1 medications semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound) are administered as injections just under the skin (subcutaneous) in three areas: Abdomen avoid the 2 inches (5 cm) directly around the navel Thigh outer/front thigh Upper arm back of the upper arm All four FDA labels (Ozempic 1 , Zepbound 2 , Mounjaro 3 , Wegovy 4 ) explicitly state that patients should rotate injection sites with each dose
But the work is still on you
Healthcare providers may perform a physical examination, order laboratory tests including complete blood count, coagulation studies (PT/INR, aPTT), and platelet count, and review medication interactions